Navigation Links
Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
Date:6/10/2008

MONTREAL, June 10 /PRNewswire/ - Aegera Therapeutics Inc. is extremely pleased to announce the initiation of a Phase 1 clinical trial of the IAP ("Inhibitor of Apoptosis Protein") inhibitor, HGS1029 (formerly AEG40826), as a monotherapy in patients with advanced solid tumors. This small molecule IAP inhibitor was developed by Aegera and licensed to Human Genome Sciences, Inc. (Nasdaq: HGSI) for oncology development in December 2007. As part of this agreement, Aegera maintains full ownership of all rights to this class of molecules for the Japanese market and global rights for non-oncology indications.

"We are impressed with the research and development teams that HGS has applied to the advancement of this exciting collaborative oncology program. In a very short period of time, their clinical team has advanced this program to its first clinical trial and we are confident that their pro-active approach will lead to the rapid and successful development of this potent molecule across a broad range of cancer indications. In addition, our respective research teams are working very closely together to continue to build on Aegera's IAP expertise and to identify additional back-up and best-in-class compounds to follow the initial lead." commented Dr. Mike Berendt, Aegera President & CEO.

Aegera also announced today the receipt of its first milestone payment under this collaboration agreement. The payment, in the amount of US$5 million, was triggered by the FDA clearance of the Investigational New Drug (IND) application for HGS1029.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In additi
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Therapeutics welcomes two experienced executives to its board of directors
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Loic Maurel Joins Exonhit Therapeutics to Become CEO
7. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
8. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 “PharmaSphere: Emerging Biotech Investment ... Capital Funding” report provides in-depth analysis of the ... and venture capital segments of the financial industry, ... have significant impact on the future of emerging ... the report identifies regions of the world that ...
(Date:7/29/2014)... 2014 Human Longevity, Inc. (HLI), a genomics ... extending the healthy, high performance human life span, today ... an expert in machine learning and machine translation as ... from Google where he was Distinguished Research Scientist and ... to HLI Co-Founder and CEO, J. Craig Venter ...
(Date:7/29/2014)... 29, 2014  The Society for Clinical Research ... program for the 9 th annual Site ... Amelia Island , Florida.  The focus on ... unchanged, however, the topics and format will allow ... among all stakeholders with a continued focus on ...
(Date:7/29/2014)... July 29, 2014  Discovery Laboratories, Inc. (Nasdaq: ... a new standard of respiratory critical care, will report ... 5, 2014 before the open of the U.S. ... host a live teleconference and webcast at 9:00 a.m. ... call, Discovery Labs, management will discuss the 2014 ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 2TransCelerate, Lilly, Pfizer, and FDA Highlight Collaborative Program at the Site Solutions Summit 3Discovery Labs to Report 2014 Second Quarter Financial Results and Hold Conference Call on Tuesday, August 5, 2014 at 9:00 a.m. Eastern Time 2
... , SAN DIEGO, Aug. 6 SEQUENOM, Inc. ... ended June 30, 2009. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO ) , ... Total revenue for the second quarter of 2009 was $9.2 million, ... the comparable period last year was primarily due to softness in capital expenditure ...
... ... Launch Of Its New And Improved Website. The New Site Provides Users With A ... Functionality And Navigation. The Site Also Offers An Expanded Service Description For Each Of ... ...
... , , LOS ANGELES, Aug. 6 ... an 82 year-old Chinese female immigrant who suffered Stevens-Johnson Syndrome/Toxic Epidermal ... Defendant, an osteopathic physician and registered pharmacist, prescribed it to her ... did not have gout. The doctor claimed that she told ...
Cached Biology Technology:SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 10One of the Nation's Leading Analytical Testing Laboratories is Now Easier to Access -- Pace Analytical Launches New Web Site to Showcase Its Three Business Divisions 2The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict 2
(Date:7/28/2014)... showing signs of damage from the Deepwater Horizon oil spill ... Gulf of Mexico. The discovery was made by a team ... University. A paper describing this work and additional impacts of ... be published during the last week of July 2014 in ... the National Academy of Sciences . , "The footprint of ...
(Date:7/28/2014)... people in the United States have a circulatory problem ... be painful and may even require surgery in serious ... wasting and, in turn, limb amputation. , At The ... Medical School, scientists tested a non-surgical preventative treatment in ... associated with increased blood circulation. Their proof-of-concept study ...
(Date:7/28/2014)... pinpointed a mechanism in part of the brain that is ... to both type 1 and type 2 diabetes. The findings ... of the National Academies of Sciences . , "We,ve ... part of the hypothalamus known as the ventromedial nucleus ... levels in the blood," said lead author Sabrina Diano, professor ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Glucose 'control switch' in the brain key to both types of diabetes 2
... (UB) has analysed which facial features our brain examines to ... maximum amount of information possible from each face and according ... in the first place, the eyes and then the shape ... study, undertaken by researcher Matthias S. Keil from the Basic ...
... 20 July 2009: Research at the University of Liverpool has ... protect buildings from earthquakes. The seismic waves produced ... and surface waves which travel across it. The new technology ... damaging and responsible for much of the destruction which follows ...
... has a long history of healing power. Its ability to heal ... back as the 10th century. Legend has it that Cleopatra used ... aloe vera was first recognized the 1930s to heal radiation burns. ... heal sunburn, minor cuts, skin irritation, and many other ailments. Recently, ...
Cached Biology News:Our brain looks at eyes first to identify a face 2Our brain looks at eyes first to identify a face 3'Invisibility cloak' could protect against earthquakes 2Healing power of aloe vera proves beneficial for teeth and gums, too 2
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
BD BioCoat Gelatin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of gelatin....
... internal standard for the quantification of 5-OxoETE ... is a polyunsaturated keto acid formed by ... It stimulates cytosolic calcium levels in neutrophils ... selectively stimulates the migration and degranulation of ...
Biology Products: